RAD50 and hepatocellular carcinoma: In the first step, the differential expression of RAD50 in normal and liver tissues was analysed; in the second step, RAD50 expression in HCC patients was assessed as an indicator of progression and prognosis; in the third step, the differential expression of RAD50 was validated in the Oncomine datasets, and GSEA was used to identify the relationships between significant genes and the involved signalling pathways.